Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover Study

CONCLUSION: From 2000 to 2018, the use of PDE5 inhibitors increased 20-fold among Danish patients with IHD who were taking nitrates. A statistically significant association between concomitant use of these medications and cardiovascular adverse events could not be identified.PRIMARY FUNDING SOURCE: Ib Mogens Kristiansens Almene Fond and Helsefonden.PMID:35436155 | DOI:10.7326/M21-3445

Source: Annals of Internal Medicine - April 18, 2022 Category: Internal Medicine Authors: Anders Holt Paul Blanche Aksel Karl Georg Jensen Nina Nouhravesh Deepthi Rajan Mads Hashiba Jensen Mohammed El-Sheikh Anne-Marie Schjerning Morten Schou Gunnar Gislason Christian Torp-Pedersen Patricia McGettigan Morten Lamberts Source Type: research